Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7693465 | 0.81 | PPARG (0.68) | PPARGKDM4EALDH1A1HPGDPDE4D | |
| SCHEMBL29592568 | 0.74 | PPARG (0.46) | PPARGKDM4EALDH1A1HPGDPDE4D | |
| SCHEMBL4065612 | 0.74 | KDM4E (0.72) | PPARGKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL11485415 | 0.74 | PPARG (0.46) | PPARGKDM4EALDH1A1SMN1; SMN2PDE4D | |
| SCHEMBL31738389 | 0.72 | KDM4E (0.59) | PPARGKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL28165065 | 0.71 | SLC2A1 (0.45) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL8542367 | 0.70 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL6577224 | 0.70 | KDM4E (0.66) | KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL4540421 | 0.70 | KDM4E (0.61) | PPARGKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL6254132 | 0.70 | MEN1 (0.40) | PPARGKDM4EALDH1A1SMN1; SMN2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627565-A1 | Use of flavanol derivatives for the cryopreservation of living cells | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2006-02-22 | — | — | EP | claimed |
| US-20250032448-A1 | COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES | KOH, Hwee Ling (SG) | 2025-01-30 | — | — | US | disclosed |
| EP-2144618-B2 | BIOEFFECTIVE KRILL OIL COMPOSITIONS | AKER BIOMARINE ANTARCTIC AS (NO) | 2024-11-20 | — | — | EP | disclosed |
| US-12144797-B2 | Compound for use in the treatment and/or prevention of parasitic mediated diseases | KOH, Hwee Ling (SG) | 2024-11-19 | — | — | US | disclosed |
| CN-118599187-A | Environment-friendly white carbon black dispersing agent and preparation method and application thereof | 青州众瑞工贸有限公司 | 2024-09-06 | — | — | CN | disclosed |
| EP-3641826-B1 | METHODS OF PRODUCING DRUG-CARRYING POLYMER SCAFFOLDS AND PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-116606548-A | Preparation method of functionalized oligomeric PPO modified phthalonitrile resin | 四川金象赛瑞化工股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-11540539-B2 | Reduced sodium food products | GENERAL MILLS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3732994-B1 | REDUCED SODIUM FOOD PRODUCTS | GEN MILLS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3466930-B1 | REDUCED SODIUM FOOD PRODUCT | GEN MILLS INC (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2014124216-A1 | REDUCED SODIUM FOOD PRODUCT | GENERAL MILLS, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014124220-A1 | REDUCED SODIUM FOOD PRODUCT | GENERAL MILLS, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014124209-A1 | REDUCED SODIUM FOOD PRODUCTS | GENERAL MILLS, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014124198-A1 | REDUCED SODIUM FOOD PRODUCT | GENERAL MILLS, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014124214-A1 | REDUCED SODIUM FOOD PRODUCTS | GENERAL MILLS, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014124205-A1 | REDUCED SODIUM FOOD PRODUCTS | GENERAL MILLS, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014124216-A1 | REDUCED SODIUM FOOD PRODUCT | GENERAL MILLS, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20100041612-A1 | Fragments of the Glucagon-Like Peptide-1 and Uses Thereof | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-6713072-B1 | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine | CHIRON S.R.L. (IT) | 2004-03-30 | — | — | US | disclosed |
| WO-2002026713-A1 | ANTIPARASITIC COMPOUNDS | KING'S COLLEGE LONDON (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144797-B2 | Compound for use in the treatment and/or prevention of parasitic mediated diseases | ICMT, ALG3, PFN1 | PPARG 3999/4885KDM4E 2090/4885ALDH1A1 583/4885 |
| US-20100041612-A1 | Fragments of the Glucagon-Like Peptide-1 and Uses Thereof | GLP1R, IAPP, GIPR | PPARG 243/4885KDM4E 4687/4885ALDH1A1 4496/4885 |
| US-20250032448-A1 | COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES | EPX, PKD2, MPO | PPARG 2964/4885KDM4E 2625/4885ALDH1A1 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.